Location History:
- Tsukuba, JP (2008 - 2011)
- Tokyo, JP (2009 - 2018)
Company Filing History:
9 out of 417 
6 out of 6 Years Active: 2008-2018
Title: Sadao Kuromitsu: Innovator in Cancer Research
Introduction
Sadao Kuromitsu is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of cancer research, particularly through his innovative work on fusion genes. With a total of nine patents to his name, Kuromitsu has established himself as a key figure in the development of novel therapeutic approaches for cancer treatment.
Latest Patents
One of Kuromitsu's latest patents focuses on the EML4-ALK fusion gene. The inventors discovered that this fusion gene, present in some cancer patients, acts as an oncogene. The invention encompasses a polypeptide that serves as a novel fusion protein, along with a polynucleotide encoding this polypeptide. Additionally, it includes a vector containing the polynucleotide and a transformed cell that comprises the vector. The patent also outlines methods for detecting the fusion protein or polynucleotide, screening therapeutic agents for cancer, and treating cancer that tests positive for the fusion gene. Furthermore, the invention includes a kit, primer set, and probe useful for detecting cancer associated with the fusion gene.
Career Highlights
Throughout his career, Sadao Kuromitsu has worked with notable companies such as Astellas Pharma GmbH and Curegene K.K. His work in these organizations has contributed to advancements in cancer therapies and diagnostics.
Collaborations
Kuromitsu has collaborated with esteemed colleagues, including Hiroyuki Mano and Nobuaki Shindo. These partnerships have further enhanced his research and innovation in the field of oncology.
Conclusion
Sadao Kuromitsu's contributions to cancer research through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for new therapeutic strategies in the fight against cancer.